Supporting awareness, personal research, and treatment of Multiple Endocrine Neoplasia Type 1
August 23, 2018
Lutetium in the treatment of neuroendocrine tumours
Lutetium-labelled peptides for therapy of neuroendocrine tumours
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304065Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with 177Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT).
Subscribe to:
Posts (Atom)